期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 9, 期 2, 页码 359-381出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.9.2.359
关键词
bone marrow microenvironment; chromosome aberration; IGF-1; IL-6; multiple myeloma (MM); translocation; vascular endothelial growth factor (VEGF)
资金
- NCI NIH HHS [P50 CA100707, R01 CA50945] Funding Source: Medline
- PHS HHS [P01 78378] Funding Source: Medline
Multiple myeloma (MM) is characterised by the expansion of monoclonal immunoglobulin-secreting plasma cells. Despite recent advances in systemic and supportive therapy, it remains incurable, with a median survival of about three years. Development of MM is a multistep process associated with an increasing frequency of chromosomal abnormalities and complex translocations, which induce mutations in several proto-oncogenes and tumour suppressor genes. Furthermore, differentiation, maintenance, expansion and drug resistance of MM cells are dependent on multiple growth factors, cytokines, and chemokines, secreted by tumour cells, bone marrow stromal cells, and non-haematopoietic organs; as well as on direct tumour cell-stromal cell contact. Therefore, signalling pathways initiated by both mutated genes in MM cells as well as signals originating in the bone marrow micro-environment represent potential targets for intervention. Close collaboration between basic researchers and clinicians will be required to further improve our knowledge of MM pathophysiologically in order to translate advances from the bench to the bedside and improve patient outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据